Drug intelligence / Profile preview

infliximab-axxq

Development stage: Approved
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Infliximab-axxq is a biosimilar monoclonal antibody to infliximab, marketed under the brand name Avsola, developed by Amgen. It is an anti-tumor necrosis factor alpha (anti-TNF) biologic used to manage and treat autoimmune and inflammatory disorders including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Infliximab-axxq binds to both the soluble and transmembrane forms of TNF-α, neutralizing its activity and blocking downstream inflammatory signaling. It is approved for all indications of the reference product, Remicade, and is given by intravenous infusion[1][3][6][8].

Brand names: Avsola
Other names: infliximab-axxq

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on infliximab-axxq.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on infliximab-axxq.

Explore the full profile